Journal
BEHAVIOURAL BRAIN RESEARCH
Volume 364, Issue -, Pages 149-156Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbr.2019.02.020
Keywords
Neurodegenerative disorders; Parkinson's disease dementia; Dementia with Lewy bodies; Alzheimer's disease; Ceftriaxone
Categories
Funding
- Ministry of Science and Technology [MOST 106-2410-H-040-003-MY2, MOST 104-2923-H-040-001-MY3, MOST 104-2314-B-040 -007-MY2]
- Chung Shan Medical University Hospital [CSH-2017-C-007]
- Taipei City Government [10501-62-046]
Ask authors/readers for more resources
Several neurodegenerative disorders, namely Parkinson's disease dementia, dementia with Lewy bodies, and Alzheimer's disease, share common pathophysiological features, such as (1) cognitive deficits, (2) glutamatergic hyperactivity-related excitotoxicity, and (3) deposition of alpha-synuclein (alpha-syn) and beta-amyloid (A beta). Ceftriaxone (CEF) is a well-tested and safe drug that has been used as an antibiotic for several decades. Recent studies have demonstrated the following effects of CEF: (1) increasing glutamate transporter-1 expression and glutamate reuptake and suppressing excitotoxicity, (2) binding well with alpha-syn and inhibition of alpha-syn polymerization, (3) modulating expression of genes related to A beta metabolism, and (4) enhancing neurogenesis and recovery of neuronal density. In addition, our data revealed that CEF ameliorates seizure and abnormal neuronal firing in the brain. These results suggest the potential of CEF in treating neuronal disorders. This paper addresses the effects and pharmacology of CEF.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available